


Ifw



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on May 9, 2005

AMENDMENT UNDER 37 CFR  
§1.825(a) THROUGH (c)  
Examining Group 1696  
Patent Application  
Docket No. UF-375  
Serial No. 10/602,394

  
Margaret Efron, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1696  
Applicants : Carrie Haskell-Luevano  
Serial No. : 10/602,394  
Filed : June 23, 2003  
Conf. No. : 1696  
For : Novel Melanocortin Receptor Templates, Peptides, and Use Thereof

Mail Stop MISSING PARTS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures that the applicant has received in the subject application.

Please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: